Vasomedical Supports Special CME Symposium on EECP to be Held in Atlanta During this Year's Scientific Sessions of the American College of Cardiology.

Business Editors & Health/Medical Writers

WESTBURY, N.Y.--(BW HealthWire)--March 6, 2002

Event Scheduled for March 16th Features Distinguished Physician

Panel

Vasomedical, Inc. (Nasdaq: VASO) announced today that a special CME (Continuing Medical Education) symposium sponsored by the University of Minnesota and supported by Vasomedical will be held Saturday evening March 16th at 5 PM at the Atlanta Sheraton Hotel during the Scientific Sessions of the American College of Cardiology in Atlanta.

The title of the upcoming symposium is "EECP: Current Experience and Future Directions". Thought leaders presenting at this symposium will review currently accepted treatment strategies for patients with symptomatic coronary artery disease and discuss the role of EECP external counterpulsation therapy in today's clinical setting. Some of the topics to be covered include a summary of clinical trial results, mechanisms of action, current use and patient selection as well as a review of ongoing and planned studies of EECP.

The symposium will be co-chaired by two past presidents of the American College of Cardiology, Anthony N. DeMaria, MD, MACC and C. Richard Conti, MD, MACC. Other members of the faculty for the event include George A. Beller, MD, MACC, immediate past president of the American College of Cardiology, Arthur M. Feldman, MD, PhD, FACC, past president of the Heart Failure Society of America, William E. Lawson, MD, FACC, Director of the Cardiac Catheterization Laboratory and Interventional Cardiology at Stony Brook University Hospital, and David R. Holmes Jr. MD, FACC Director of the Cardiac Catheterization Laboratory at the Mayo Clinic and past-president of the Society for Cardiac Angiography and Interventions.

Commenting on the upcoming symposium, Thomas R. Varricchione, Vice President for Regulatory and Clinical Affairs at Vasomedical, stated "This is the first time that Vasomedical is supporting a CME event of this magnitude and given the increase in the number of clinicians offering EECP therapy, the timing of such an event is very appropriate. EECP is a proven treatment for patients with symptomatic coronary artery disease and this symposium will afford clinicians an opportunity to learn about the current state of EECP therapy from an outstanding faculty of their colleagues." Additional information about this symposium is available by clicking http://www.med.umn.edu/cme/brochures2002/eecp2002/eecpbro2002.html.

Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting EECP external counterpulsation systems based on the Company's proprietary technology currently indicated for use in cases of angina, cardiogenic shock and acute myocardial infarction. EECP is a noninvasive, outpatient therapy for the treatment of diseases of the cardiovascular system. The therapy serves to increase circulation in areas of the heart with less than adequate blood supply and may restore systemic vascular function. The Company is also actively engaged in research to determine potential benefits of EECP therapy in the management of other major vascular disease states, including congestive heart failure and diabetes. The Company provides hospitals, clinics and private practices with EECP(R) equipment, treatment guidance and a staff training and maintenance program designed to provide optimal patient outcomes. EECP(R) is a registered trademark for Vasomedical's enhanced external counterpulsation system. Additional information is available on the Company's website at www.vasomedical.com.

Except for historical information contained in this release, the matters discussed are forward looking statements that involve risks and uncertainties. When used in this release, words such as "anticipate," "believe," "estimate," "expect" and "intend" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.